Last reviewed · How we verify
NCT06972368: TENTADIS
Home-Based tDCS for Depression in BPD
NA trial testing tDCS in Major Depressive Disorder (MDD) in 60 participants. Currently enrolling.
1 January 2027
Quick facts
| Lead sponsor | Ciusss de L'Est de l'Île de Montréal |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 January 2026 |
| Primary completion | 1 January 2027 |
| Estimated completion | 1 June 2027 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- tDCS — full drug profile →
- Treatment as Usual (TAU) — full drug profile →
- Psychoeducation
- Sham-tDCS
Conditions studied
- Major Depressive Disorder (MDD) — all drugs for Major Depressive Disorder (MDD) →
- Borderline Personality Disorders — all drugs for Borderline Personality Disorders →
Sponsor
Ciusss de L'Est de l'Île de Montréal — full company profile →
Who can join
Adults 18 to 65, any sex, with Major Depressive Disorder (MDD) or Borderline Personality Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The present study aims to assess the feasibility of home-based tDCS in remote and urban areas (primary objective). The secondary aim is to obtain a preliminary assessment of the efficacy of 14 home-based tDCS sessions in reducing depressive symptoms in BPD patients with moderate to severe depressive episodes and BPD symptoms. Exploratory objectives include assessing the impact on neuropsychological and psychosocial functioning, anxiety, physical activity, sleep disorders, and addiction. Additionally, we aim to investigate the sociodemographic and clinical factors that are linked to the most favorable response to tDCS in addressing both depressive and BPD symptoms. We also aim to assess the feasibility of using a smartwatch as an outcome measure in this population. Finally, we intend to gather preliminary data on the effectiveness of an online psychoeducational program specifically designed for patients with BPD. Researchers will compare active tDCS to sham tDCS to see if active treatment is more effective in treating depression in this population. Participants will: * Receive 14 sessions of either active or sham tDCS over one week, delivered at home * Complete psychological and neurocognitive assessments at baseline, post-treatment, and at 6 weeks * Wear actigraphy monitors and complete questionnaires to assess sleep, physical activity, and other mental health outcomes This trial will also explore the feasibility of delivering tDCS in both urban and rural settings.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06972368
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of tDCS
Trials testing the same drug.
- NCT07400939 — Brain Stimulation Combined With Watching Hand Movements to Improve Hand Recovery in Chronic Stroke · NA · recruiting
- NCT06994390 — Neuropathic Pain Intervention With tDCS in Brazilian Military Personnel (NeuBRAIN Trial) · NA · not yet recruiting
- NCT07358832 — Neuromodulation Through Multisensory Stimulation for Visual Field Deficits in the Subacute Stage of Disease · NA · recruiting
- NCT07331779 — Effect of tDCS Timing on Motor Recovery in Acute Stroke Rehabilitation · NA · not yet recruiting
- NCT06239675 — Cerebral pAlsy Motor Promotion With Transcranial Direct Current Stimulation (CAMP-tDCS) · NA · withdrawn
Other recruiting trials for Major Depressive Disorder (MDD)
Currently open trials in the same condition.
- NCT07396272 — A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression · Phase 2 · recruiting
- NCT07226661 — Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder · Phase 2 · recruiting
- NCT07324070 — Electroconvulsive Therapy Augmented With Transcranial Magnetic Stimulation for Treatment Resistant Depression · NA · recruiting
- NCT07294924 — Prediction of REsponse to Depression Interventions (Accelerated rTMS) Using Clinical and TD-fNIRS Measurements · recruiting
- NCT06773949 — Feasibility Trial of Exercise as a Priming Strategy for rTMS Treatment in Difficult-to-Treat Depression · NA · recruiting
Other Ciusss de L'Est de l'Île de Montréal trials
Trials by the same sponsor.
- NCT06500143 — Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery · completed
- NCT06522698 — Optimizing Research Data Acquisition With Smart Pill Bottles · NA · not yet recruiting
- NCT06522711 — Virtual Reality for Anxiolysis and Pharmacological Sparing · NA · not yet recruiting
- NCT07112261 — Avatar Therapy in Virtual Reality for Treatment-Resistant Major Depressive Disorder: A Pilot Study · NA · active not recruiting
- NCT06318806 — Towards Remission and Full Recovery From Obsessive-compulsive Disorder · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06972368 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ciusss de L'Est de l'Île de Montréal
- Last refreshed: 28 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06972368.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing